11-0628-41
antibody from Invitrogen Antibodies
Targeting: SELP
CD62, CD62P, GMP140, GRMP, PADGEM, PSEL
Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 11-0628-41 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Anti-CD62P (P-Selectin) Monoclonal Antibody (AK-4), FITC, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The AK-4 monoclonal antibody reacts with human CD62P, a 140 kDa transmembrane glycoprotein also known as P-Selectin. Upon activation, CD62P is rapidly transported from its cytoplasmic stores in the Weibel-Palade bodies of endothelial cells or the alpha-granules of platelets to the surface. CD62P initiates the adhesive interaction between endothelial cells and neutrophils and monocytes during the inflammatory reaction and is also involved in the interaction of platelets with monocytes and neutrophils. Applications Reported: The AK-4 antibody has been reported for use in flow cytometric analysis. Applications Tested: This AK-4 antibody has been pre-titrated and tested by flow cytometric analysis of resting and thrombin-activated human platelets. This can be used at 5 µL (1 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Excitation: 488 nm; Emission: 520 nm; Laser: Blue Laser. Filtration: 0.2 µm post-manufacturing filtered.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Green dye
- Isotype
- IgG
- Antibody clone number
- AK-4
- Vial size
- 25 Tests
- Concentration
- 5 µL/Test
- Storage
- 4° C, store in dark, DO NOT FREEZE!
Submitted references Activation of platelet protease-activated receptor-1 induces epithelial-mesenchymal transition and chemotaxis of colon cancer cell line SW620.
Jia Y, Zhang S, Miao L, Wang J, Jin Z, Gu B, Duan Z, Zhao Z, Ma S, Zhang W, Li Z
Oncology reports 2015 Jun;33(6):2681-8
Oncology reports 2015 Jun;33(6):2681-8
No comments: Submit comment
No validations: Submit validation data